tiprankstipranks
Blurbs

BMO Capital Reaffirms Their Hold Rating on Gilead Sciences (GILD)

In a report released today, Evan Seigerman from BMO Capital maintained a Hold rating on Gilead Sciences (GILDResearch Report), with a price target of $65.00. The company’s shares closed last Monday at $61.45, close to its 52-week low of $59.18.

According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 7.0% and a 43.5% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Mirati Therapeutics, and Merck & Company.

Currently, the analyst consensus on Gilead Sciences is a Moderate Buy with an average price target of $73.13, which is a 18.2% upside from current levels. In a report issued on March 1, Robert W. Baird also maintained a Hold rating on the stock with a $63.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $74.12 and a one-year low of $59.18. Currently, Gilead Sciences has an average volume of 9.54M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Founded in 1987, California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human immunodeficiency virus (HIV), hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It offers its products under brands including Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi.

Read More on GILD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More